Cited by 165RNA Interference and Gene DeliveryAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 135 of the 136 references it cites were found in a registry or an index.

Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA

Open access

DeVos, Sarah L., Miller, Timothy M.·2013·Neurotherapeutics

DOI 10.1007/s13311-013-0194-5PMC PMC3701770

Open this paper in CoChat — free account Open PDF

Abstract

Adequate therapies are lacking for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases. The ability to use antisense oligonucleotides (ASOs) to target disease-associated genes by means of RNA may offer a potent approach for the treatment of these, and other, neurodegenerative disorders. In modifying the basic backbone chemistry, chemical groups, and target sequence, ASOs can act through numerous mechanisms to decrease or increase total protein levels, preferentially shift splicing patterns, and inhibit microRNAs, all at the level of the RNA molecule. Here, we discuss many of the more commonly used ASO chemistries, as well as the different mechanisms of action that can result from these specific chemical modifications. When applied to multiple neurodegenerative mouse models, ASOs that specifically target the detrimental transgenes have been shown to rescue disease associated phenotypes in vivo. These supporting mouse model data have moved the ASOs from the bench to the clinic, with two neuro-focused human clinical trials now underway and several more being proposed. Although still early in development, translating ASOs into human patients for neurodegeneration appears promising.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s13311-013-0194-5

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alternative isoform regulation in human tissue transcriptomes
Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,871
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Gene silencing by microRNAs: contributions of translational repression and mRNA decay
Huntzinger, E., & Izaurralde, E. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2936 · Cited by 2,339
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E., Zeuzem, S., Rodriguez‐Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A. P., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,262
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168

Show all 136 references

Research works printed but not linked: 1

Esau, 2006, miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metabol, 3, 87, 10.1016/j.cmet.2006.01.005 · DOI · Paper page

Sorted by citations

Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Self-citation
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bézard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 399
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
Lu, D., & Thum, T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0218-x · Cited by 341
Antisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311
Self-citation
Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets
Fatima, R., Akhade, V. S., Pal, D., & Rao, S. M. R. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0042-6 · Cited by 269
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model
Schoch, K. M., DeVos, S. L., Miller, R. L., Chun, S. J., Norrbom, M., Wozniak, D. F., Dawson, H. N., Bennett, C. F., Rigo, F., & Miller, T. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.042 · Cited by 175
Self-citation
Noncoding RNAs in neurodegeneration
Salta, E., & De Strooper, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.90 · Cited by 183
Nucleic‐Acid Structures as Intracellular Probes for Live Cells
Samanta, D., Ebrahimi, S. B., & Mirkin, C. A. (2019) · Advanced Materials · doi:10.1002/adma.201901743 · Cited by 154
Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Southwell, A. L., Skotte, N. H., Kordasiewicz, H. B., Østergaard, M. E., Watt, A. T., Carroll, J. B., Doty, C. N., Villanueva, E. B., Petoukhov, E., Vaid, K., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.153 · Cited by 150
Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS
Coyne, A. N., Baskerville, V., Zaepfel, B. L., Dickson, D. W., Rigo, F., Bennett, F., Lusk, C. P., & Rothstein, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1923 · Cited by 143
Tau: From research to clinical development
Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., Goedert, M., Mandelkow, E., Mandelkow, E., Miller, D. S., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.018 · Cited by 139
Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides
Hinrich, A. J., Jodelka, F. M., Chang, J. L., Brutman, D., Bruno, A. M., Briggs, C. A., James, B. D., Stutzmann, G. E., Bennett, D. A., Miller, S. A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505846 · Cited by 127
Antisense oligonucleotides in neurological disorders
Wurster, C. D., & Ludolph, A. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418776932 · Cited by 133
The prion model for progression and diversity of neurodegenerative diseases
Stopschinski, B. E., & Diamond, M. I. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30037-6 · Cited by 133
Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging
Mazur, C., Powers, B., Zasadny, K., Sullivan, J. M., Dimant, H., Kamme, F., Hesterman, J., Matson, J., Oestergaard, M., Seaman, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129240 · Cited by 114
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges
Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 116
Progressive supranuclear palsy: Advances in diagnosis and management
Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 118
Evidence for a Regulatory Role of Diatom Silicon Transporters in Cellular Silicon Responses
Shrestha, R. P., & Hildebrand, M. (2014) · Eukaryotic Cell · doi:10.1128/ec.00209-14 · Cited by 105
Aberrant alternative splicing in breast cancer
Yang, Q., Zhao, J., Zhang, W., Chen, D., & Wang, Y. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz033 · Cited by 107
Skipping Multiple Exons to Treat DMD—Promises and Challenges
Aslesh, T., Maruyama, R., & Yokota, T. (2018) · Biomedicines · doi:10.3390/biomedicines6010001 · Cited by 100
Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms
Figueroa‐Romero, C., Hur, J., Lunn, J. S., Paez-Colasante, X., Bender, D. E., Yung, R. L., Sakowski, S. A., & Feldman, E. L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.12.008 · Cited by 106
Nuclear pore complexes — a doorway to neural injury in neurodegeneration
Coyne, A. N., & Rothstein, J. D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00653-6 · Cited by 96
The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy
Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 96
AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy
Pattali, R. K., Mou, Y., & Li, X.-J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0085-4 · Cited by 100
Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91
Antisense targeting of 3′ end elements involved inDUX4mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach
Marsollier, A.-C., Ciszewski, L., Mariot, V., Popplewell, L. J., Voït, T., Dickson, G., & Dumonceaux, J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw015 · Cited by 89
Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development
Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., & Carril, J. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_13 · Cited by 86
Mitigating off‐target effects of small RNAs: conventional approaches, network theory and artificial intelligence
Bereczki, Z., Benczik, B., Balogh, O. M., Marton, S., Puhl, E., Pétervári, M., Váczy‐Földi, M., Papp, Z. T., Makkos, A., Glass, K., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17302 · Cited by 83
Recent advances in the discovery and development of factor XI/XIa inhibitors
Al‐Horani, R. A., & Afosah, D. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21503 · Cited by 82
β2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice
Zhao, Y., Zheng, Q., Hong, Y., Gao, Y., Hu, J., Lang, M., Zhang, H., Zhou, Y., Luo, H., Zhang, X., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01352-1 · Cited by 85
Silencing strategies for therapy of SOD1-mediated ALS
van Zundert, B., & Brown, R. H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.059 · Cited by 81
Current directions in tau research: Highlights from Tau 2020
Sexton, C. E., Snyder, H. M., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12452 · Cited by 89
Self-citation
Persistent repression of tau in the brain using engineered zinc finger protein transcription factors
Wegmann, S., DeVos, S. L., Zeitler, B., Marlen, K., Bennett, R. E., Perez-Rando, M., MacKenzie, D., Yu, Q., Commins, C., Bannon, R. N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1611 · Cited by 77
Self-citation
Factor XIa inhibitors: A review of the patent literature
Al‐Horani, R. A., & Desai, U. R. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1154045 · Cited by 76
Antisense Therapy in Neurology
Lee, J. K., & Yokota, T. (2013) · Journal of Personalized Medicine · doi:10.3390/jpm3030144 · Cited by 76
Development and Characterization of Gene Silencing DNA Cages
Fakhoury, J. J., McLaughlin, C. K., Edwardson, T. G. W., Conway, J. W., & Sleiman, H. F. (2013) · Biomacromolecules · doi:10.1021/bm401532n · Cited by 75
De-repressing LncRNA-Targeted Genes to Upregulate Gene Expression: Focus on Small Molecule Therapeutics
Fatemi, R. P., Velmeshev, D., & Faghihi, M. A. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.45 · Cited by 76
Oligonucleotide therapeutics in neurodegenerative diseases
Scoles, D. R., & Pulst, S. M. (2018) · RNA Biology · doi:10.1080/15476286.2018.1454812 · Cited by 70
Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders
Silva, A. C., Lobo, D. D., Martins, I. M., Lopes, S., Henriques, C., Duarte, S., Dodart, J., Nobre, R. J., & de Almeida, L. P. (2019) · Brain · doi:10.1093/brain/awz328 · Cited by 72
Harnessing the integrated stress response for the treatment of multiple sclerosis
Way, S. W., & Popko, B. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00381-6 · Cited by 71
Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update
Schätzl, T., Kaiser, L., & Deigner, H. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01760-1 · Cited by 70
Alternative Splicing in Alzheimer’s Disease
Love, J. E., Hayden, E. J., & Rohn, T. T. (2015) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000010 · Cited by 69
Emerging Roles of RNA 3′-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders
Nourse, J. P., Spada, S., & Danckwardt, S. (2020) · Biomolecules · doi:10.3390/biom10060915 · Cited by 68
Nucleic Acid Templated Reactions for Chemical Biology
Pisa, M. D., & Seitz, O. (2017) · ChemMedChem · doi:10.1002/cmdc.201700266 · Cited by 64
From Junk to Function: LncRNAs in CNS Health and Disease
Policarpo, R., Sierksma, A. S. R., Strooper, B. D., & d’Ydewalle, C. V. O. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.714768 · Cited by 63
Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis
Hoye, M. L., Regan, M. R., Jensen, L. A., Lake, A. M., Reddy, L. V., Vidensky, S., Richard, J.-P., Maragakis, N. J., Rothstein, J. D., Dougherty, J. D., et al. (2018) · Brain · doi:10.1093/brain/awy182 · Cited by 63
Self-citation
RAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
In vivo kinetic approach reveals slow SOD1 turnover in the CNS
Crisp, M. J., Mawuenyega, K. G., Patterson, B. W., Reddy, N. C., Chott, R. C., Self, W. K., Weihl, C. C., Jockel, J., Varadhachary, A. S., Bucelli, R. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80705 · Cited by 59
Self-citation
Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside
Çakan, E., Lara, O. D., Szymanowska, A., Bayraktar, E., Chávez‐Reyes, A., Lopez‐Berestein, G., Amero, P., & Rodriguez‐Aguayo, C. (2024) · Cancers · doi:10.3390/cancers16172940 · Cited by 57
Effects on Murine Behavior and Lifespan of Selectively Decreasing Expression of Mutant Huntingtin Allele by Supt4h Knockdown
Cheng, H., Chern, Y., Chen, I.-H., Liu, C.-R., Li, S.-H., Chun, S. J., Rigo, F., Bennett, C. F., Deng, N., Feng, Y., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005043 · Cited by 50
Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
Ezerskiy, L. A., Schoch, K. M., Sato, C., Beltcheva, M., Horie, K., Rigo, F., Martynowicz, R., Karch, C. M. M., Bateman, R. J., & Miller, T. M. (2021) · JCI Insight · doi:10.1172/jci.insight.152012 · Cited by 48
Self-citation
Advancement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialoglycoprotein receptor
Zhang, Y., Liu, H., Zhen, W., Jiang, T., & Cui, J. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109426 · Cited by 46
G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons
Rothstein, J. D., Baskerville, V., Rapuri, S., Mehlhop, E., Jafar‐Nejad, P., Rigo, F., Bennett, F., Mizielinska, S., Isaacs, A. M., & Coyne, A. N. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02652-3 · Cited by 43
Mechanisms of Antisense Transcription Initiation with Implications in Gene Expression, Genomic Integrity and Disease Pathogenesis
Barman, P., Reddy, D., & Bhaumik, S. R. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010011 · Cited by 39
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 40
Therapeutic Strategies Targeting DUX4 in FSHD
Gall, L. L., Sidlauskaite, E., Mariot, V., & Dumonceaux, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092886 · Cited by 37
Current Management and Emerging Therapies in Multiple System Atrophy
Burns, M. R., & McFarland, N. R. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00890-x · Cited by 34
Advances in intelligent DNA nanomachines for targeted cancer therapy
Chen, B., Lan, M., Wang, Y., & Guo, G. F. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.006 · Cited by 30
Targeting long non-coding RNA ASBEL with oligonucleotide antagonist for breast cancer therapy
Xia, Y., Xiao, X., Deng, X., Zhang, F., Zhang, X., Hu, Q., & Wang, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.136 · Cited by 29
Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2—A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling
Kuespert, S., Heydn, R., Peters, S., Wirkert, E., Meyer, A.-L., Siebörger, M., Johannesen, S. W., Aigner, L., Bogdahn, U., & Bruun, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061952 · Cited by 29
Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells
García-Garrido, E., Cordani, M., & Somoza, Á. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122067 · Cited by 29
Perfluoroalkylchain conjugation as a new tactic for enhancing cell permeability of peptide nucleic acids (PNAs) via reducing the nanoparticle size
Ellipilli, S., Murthy, R. V., & Ganesh, K. N. (2015) · Chemical Communications · doi:10.1039/c5cc05342k · Cited by 28
I-Motif-Based in Situ Bipedal Hybridization Chain Reaction for Specific Activatable Imaging and Enhanced Delivery of Antisense Oligonucleotides
Ma, W., Chen, B., Zou, S., Jia, R., Cheng, H., Huang, J. L., Wang, H., He, X., & Wang, K. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03420 · Cited by 28
Enzymatic synthesis of random sequences of RNA and RNA analogues by DNA polymerase theta mutants for the generation of aptamer libraries
Randrianjatovo-Gbalou, I., Rosario, S., Sismeiro, O., Varet, H., Legendre, R., Coppée, J., Huteau, V., Pochet, S., & Delarue, M. H. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky413 · Cited by 27
The role of UBE3A in the autism and epilepsy-related Dup15q syndrome using patient-derived, CRISPR-corrected neurons
Elamin, M., Dumarchey, A., Stoddard, C. E., Robinson, T. M., Cowie, C., Gorka, D., Chamberlain, S. J., & Levine, E. S. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.02.002 · Cited by 25
Hidden regulators: the emerging roles of lncRNAs in brain development and disease
Alammari, F., Al-Hujaily, E. M., Alshareeda, A. T., Albarakati, N., & Al-Sowayan, B. S. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1392688 · Cited by 29
Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress
Dume, B. R., Licărete, E., & Banciu, M. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102256 · Cited by 25
Antisense Oligonucleotide In Vitro Protein Binding Determination in Plasma, Brain, and Cerebral Spinal Fluid Using Hybridization LC-MS/MS
Guimaraes, G. J., Yuan, L., & Li, P. S. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000751 · Cited by 25
Targeting the Polyadenylation Signal of Pre-mRNA: A New Gene Silencing Approach for Facioscapulohumeral Dystrophy
Marsollier, A.-C., Joubert, R., Mariot, V., & Dumonceaux, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051347 · Cited by 26
MicroRNAs in diagnosis and therapeutics
Atri, C., Guerfali, F. Z., & Laouini, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815669-8.00006-3 · Cited by 25
RNA-targeted Therapeutics for ALS
Reddy, L. V., & Miller, T. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0344-z · Cited by 25
Self-citation
Unlocking the therapeutic potential of locked nucleic acids through lipid nanoparticle delivery
Qassem, S., Breier, D., Naidu, G. S., Hazan‐Halevy, I., & Peer, D. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102224 · Cited by 23
Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma
Hedna, R., Kovacic, H., Pagano, A., Peyrot, V., Robin, M., Devred, F., & Breuzard, G. (2022) · Cancers · doi:10.3390/cancers14215386 · Cited by 25
An Updated Analysis of Exon-Skipping Applicability for Duchenne Muscular Dystrophy Using the UMD-DMD Database
Leckie, J., Zia, A., & Yokota, T. (2024) · Genes · doi:10.3390/genes15111489 · Cited by 22
Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes
Magner, D., Biała, E., Lisowiec‐Wąchnicka, J., & Kierzek, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-12844-z · Cited by 22
Novel Therapeutic Horizons: SNCA Targeting in Parkinson’s Disease
Caramiello, A. M., & Pirota, V. (2024) · Biomolecules · doi:10.3390/biom14080949 · Cited by 22
An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
Poplawski, S. G., Garbett, K. A., McMahan, R. L., Kordasiewicz, H. B., Zhao, H. T., Kennedy, A. J., Goleva, S. B., Sanders, T. H., Motley, S. T., Swayze, E. E., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.01.027 · Cited by 21
Silencing of Thrips palmi UHRF1BP1 and PFAS Using Antisense Oligos Induces Mortality and Reduces Tospovirus Titer in Its Vector
Priti, P., Mukherjee, S. K., & Ghosh, A. (2022) · Pathogens · doi:10.3390/pathogens11111319 · Cited by 20
Antisense oligonucleotide development for the treatment of muscular dystrophies
Le, B. T., Veedu, R. N., Fletcher, S., & Wilton, S. D. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1122517 · Cited by 19
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials
Buxbaum, J. N. (2019) · Amyloid · doi:10.1080/13506129.2019.1575201 · Cited by 19
An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Li, Y., Zeng, H., Wei, Y., Ma, X., & He, Z. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.189 · Cited by 19
New Roles for Canonical Transcription Factors in Repeat Expansion Diseases
Goodman, L. D., & Bonini, N. M. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.11.003 · Cited by 18
Metallacarborane Complex Boosts the Rate of DNA Oligonucleotide Hydrolysis in the Reaction Catalyzed by Snake Venom Phosphodiesterase
Kaniowski, D., Kulik, K., Ebenryter‐Olbińska, K., Wielgus, E., Lesnikowski, Z. J., & Nawrot, B. (2020) · Biomolecules · doi:10.3390/biom10050718 · Cited by 19
Machine learning in early diagnosis of neurological diseases: Advancing accuracy and overcoming challenges
Li, Y., Chang, X., Wu, J., Liu, Y., Wang, H., & Zhang, Y. (2025) · Brain Network Disorders · doi:10.1016/j.bnd.2025.04.001 · Cited by 19
Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury
Moreno, P. M. D., Ferreira, A. K. D. S., Salvador, D., Rodrigues, M. T., Torrado, M., Carvalho, E. D., Tedebark, U., Sousa, M. M., Amaral, I. F., Wengel, J., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.03.009 · Cited by 17
Correction of a Splicing Mutation Affecting an Unverricht-Lundborg Disease Patient by Antisense Therapy
Matos, L., Duarte, A. J., Ribeiro, D., Chaves, J., Amaral, O., & Alves, S. (2018) · Genes · doi:10.3390/genes9090455 · Cited by 17
Insights into role of microRNA in Alzheimer's disease: From contemporary research to bedside perspective
Bandakinda, M., & Mishra, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126561 · Cited by 16
Targeting Alternative Splicing as a Potential Therapy for Episodic Ataxia Type 2
Jaudon, F., Baldassari, S., Musante, I., Thalhammer, A., Zara, F., & Cingolani, L. A. (2020) · Biomedicines · doi:10.3390/biomedicines8090332 · Cited by 16
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease
Vandermeulen, L., Geric, I., Fumagalli, L., Kreir, M., Lu, A., Nonneman, A., Premereur, J., Wolfs, L., Policarpo, R., Fattorelli, N., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00725-9 · Cited by 16
Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly
Wang, Y., Shen, W., Liang, X.-H., & Crooke, S. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0806 · Cited by 13
Chitosan-Shelled Nanobubbles Irreversibly Encapsulate Morpholino Conjugate Antisense Oligonucleotides and Are Ineffective for Phosphorodiamidate Morpholino-Mediated Gene Silencing of DUX4
Falzarano, M. S., Argenziano, M., Marsollier, A.-C., Mariot, V., Rossi, D., Selvatici, R., Dumonceaux, J., Cavalli, R., & Ferlini, A. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0862 · Cited by 14
Influence of conjugation and other structural changes on the activity of Cu 2+ based PNAzymes
Ghidini, A., Murtola, M., & Strömberg, R. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02394g · Cited by 14
Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection
Arriaga-Canon, C., Contreras‐Espinosa, L., Rebollar‐Vega, R., Montiel-Manríquez, R., Cedro‐Tanda, A., García-Gordillo, J. A., Álvarez-Gómez, R. M., Jiménez-Trejo, F. J., Hernández, C. C., & Herrera, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911058 · Cited by 14
FTLD Treatment: Current Practice and Future Possibilities
Ljubenkov, P. A., & Boxer, A. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_18 · Cited by 16
Genetic therapy for congenital myopathies
Maani, N., Karolczak, S., & Dowling, J. J. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000978 · Cited by 14
Regulation of Antisense Transcription by NuA4 Histone Acetyltransferase and Other Chromatin Regulatory Factors
Uprety, B., Kaja, A., Ferdoush, J., Sen, R., & Bhaumik, S. R. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00808-15 · Cited by 12
LncRNAs as Therapeutic Targets for Autophagy-involved Cardiovascular Diseases: A Review of Molecular Mechanism and T herapy Strategy
Jin, L., Hong, N., Ai, X., Wang, J., Li, Z., Han, Z., Zhang, Q., Yu, Y., & Sun, K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200320161835 · Cited by 11

Authors: DeVos, S. L., & Miller, T. M.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Miller, Timothy M.
ORCID: DeVos, Sarah L.
Miller, Timothy M.
Venue: Neurotherapeutics
Publisher: Elsevier BV
Published: 2013-07
Volume: 10
Issue: 3
Pages: 486-497
ISSN: 1878-7479 (ISSN-L)
DOI: 10.1007/s13311-013-0194-5
PMC: PMC3701770
OpenAlex: W2093892225
Cited by: 164
References: 136
Citations by year: 2026: 8 · 2025: 11 · 2024: 11 · 2023: 9 · 2022: 11 · 2021: 16 · 2020: 14 · 2019: 17 · 2018: 13 · 2017: 14 · 2016: 17 · 2015: 12 · 2014: 8 · 2013: 3
FWCI: 1.26
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3699 d)
Locations: Neurotherapeutics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Institute on Aging (P50AG005681)
National Institute of Neurological Disorders and Stroke (NIH/NINDS K08NS074194, NIH/NINDS R01NS078398, K08NS074194, R01NS078398)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords: antisense oligonucleotides, neurodegenerative diseases, RNA-targeted therapeutics, splicing modulation, microRNA inhibition, mouse models of human disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis
MeSH terms: Animals, Humans, RNA, Neuroprotective Agents, Neurodegenerative Diseases, Oligodeoxyribonucleotides, Antisense

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks